Clinical significance and predictors of complete or near-complete histological response to preoperative chemoradiotherapy in patients with localized pancreatic ductal adenocarcinoma

被引:7
作者
Murata, Yasuhiro [1 ]
Mizuno, Shugo [1 ]
Kishiwada, Masashi [1 ]
Uchida, Katsunori [2 ]
Noguchi, Daisuke [1 ]
Gyoten, Kazuyuki [1 ]
Hayasaki, Aoi [1 ]
Fujii, Takehiro [1 ]
Iizawa, Yusuke [1 ]
Tanemura, Akihiro [1 ]
Kuriyama, Naohisa [1 ]
Sakurai, Hiroyuki [1 ]
Isaji, Shuji [3 ]
机构
[1] Mie Univ, Dept Hepatobiliary Pancreat & Transplant Surg, Grad Sch Med, 2-174 Edobashi, Tsu, Mie 5148507, Japan
[2] Mie Univ, Dept Oncol Pathol, Grad Sch Med, 2-174 Edobashi, Tsu, Mie 5148507, Japan
[3] Mie Univ Hosp, 2-174 Edobashi, Tsu, Mie 5148507, Japan
关键词
Localized pancreatic adenocarcinoma; Preoperative chemoradiotherapy; Histological response; R0; resection; Predictors; NEOADJUVANT THERAPY; CANCER; GEMCITABINE; S-1; CHEMOTHERAPY; SURVIVAL; PANCREATICODUODENECTOMY; CHEMORADIATION; 5-FLUOROURACIL; METAANALYSIS;
D O I
10.1016/j.pan.2021.08.011
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The clinical value and predictors of a favorable histological response to preoperative chemoradiotherapy (CRT) in pancreatic ductal adenocarcinoma (PDAC) remains undefined. Objective: To assess the significance and predictors of a favorable histological response to preoperative CRT in patients with localized PDAC. Methods: The study included 203 patients with localized PDAC undergoing curative-intent resection after CRT. The rate of R0 resection and overall survival (OS) and recurrence-free survival (RFS) were correlated with the grading of histological response to determine optimal stratification. Clinical factors associated with a significant histological response were evaluated using multivariate regression analysis. Results: Among all patients, eight patients (3.9%) had a grade 4 (pCR); 40 (19.4%) had a grade 3 estimated rate of residual neoplastic cells < 10% (near-pCR); and 155 (76.7%) had a grade 1/2 limited response. The 48 patients with pCR/near-pCR achieved significantly higher R0 resection rate (100%) than those with grade 1/2 (80.0%). The 5-year OS and RFS rates were significantly higher in the patients with pCR/nearpCR (45.3% and 36.5%) than in those with grade 1/2 (27.1% and 18.5%). Gemcitabine plus S-1 based CRT, serum CA19-9 level after CRT < 83 U/mL, and interval from initial treatment to surgery > 4.4 months were independent predictive factors for pCR/near-pCR. Conclusions: pCR or near-pCR to preoperative CRT contributed to achieving a high rate of R0 resection and improving survival for localized PDAC. The use of gemcitabine plus S-1 as a radiosensitizer, lower serum CA19-9 level after CRT, and longer preoperative treatment duration were significantly associated with pCR or near-pCR. (c) 2021 IAP and EPC. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1482 / 1490
页数:9
相关论文
共 34 条
  • [21] Pathological Complete Remission of Pancreatic Cancer Following Neoadjuvant Chemoradiation Therapy; Not the End of Battles
    Lee, Sung Hwan
    Kang, Chang Moo
    Kim, Hogeun
    Hwang, Ho Kyoung
    Song, Si Young
    Seong, Jinsil
    Kim, Myoung Jin
    Lee, Woo Jung
    [J]. MEDICINE, 2015, 94 (52)
  • [22] Reappraisal of Nodal Staging and Study of Lymph Node Station Involvement in Pancreaticoduodenectomy with the Standard International Study Group of Pancreatic Surgery Definition of Lymphadenectomy for Cancer
    Malleo, Giuseppe
    Maggino, Laura
    Capelli, Paola
    Gulino, Francesco
    Segattini, Silvia
    Scarpa, Aldo
    Bassi, Claudio
    Butturini, Giovanni
    Salvia, Roberto
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2015, 221 (02) : 367 - U632
  • [23] Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy
    Mellon, Eric A.
    Jin, William H.
    Frakes, Jessica M.
    Centeno, Barbara A.
    Strom, Tobin J.
    Springett, Gregory M.
    Malafa, Mokenge P.
    Shridhar, Ravi
    Hodul, Pamela J.
    Hoffe, Sarah E.
    [J]. ACTA ONCOLOGICA, 2017, 56 (03) : 391 - 397
  • [24] Anterior Approach to the Superior Mesenteric Artery by Using Nerve Plexus Hanging Maneuver for Borderline Resectable Pancreatic Head Carcinoma
    Mizuno, Shugo
    Isaji, Shuji
    Tanemura, Akihiro
    Kishiwada, Masashi
    Murata, Yasuhiro
    Azumi, Yoshinori
    Kuriyama, Naohisa
    Usui, Masanobu
    Sakurai, Hiroyuki
    Tabata, Masami
    [J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2014, 18 (06) : 1209 - 1215
  • [25] Neoadjuvant Chemotherapy with Gemcitabine and S-1 for Resectable and Borderline Pancreatic Ductal Adenocarcinoma: Results from a Prospective Multi-institutional Phase 2 Trial
    Motoi, Fuyuhiko
    Ishida, Kazuyuki
    Fujishima, Fumiyoshi
    Ottomo, Shigeru
    Oikawa, Masaya
    Okada, Takaho
    Shimamura, Hiromune
    Takemura, Shinichi
    Ono, Fuminori
    Akada, Masanori
    Nakagawa, Kei
    Katayose, Yu
    Egawa, Shinichi
    Unno, Michiaki
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (12) : 3794 - 3801
  • [26] Impact of Histological Response After Neoadjuvant Chemoradiotherapy on Recurrence-Free Survival in UICC-T3 Pancreatic Adenocarcinoma But Not in UICC-T4
    Murata, Yasuhiro
    Mizuno, Shugo
    Kishiwada, Masashi
    Hamada, Takashi
    Usui, Masanobu
    Sakurai, Hiroyuki
    Tabata, Masami
    Inoue, Hiroyuki
    Shiraishi, Taizo
    Isaji, Shuji
    [J]. PANCREAS, 2012, 41 (01) : 130 - 136
  • [27] Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery
    Nagakawa, Yuichi
    Sahara, Yatsuka
    Hosokawa, Yuichi
    Murakami, Yoshiaki
    Yamaue, Hiroki
    Satoi, Sohei
    Unno, Michiaki
    Isaji, Shuji
    Endo, Itaru
    Sho, Masayuki
    Fujii, Tsutomu
    Takishita, Chie
    Hijikata, Yosuke
    Suzuki, Shuji
    Kawachi, Shigeyuki
    Katsumata, Kenji
    Ohta, Tetsuo
    Nagakawa, Takukazu
    Tsuchida, Akihiko
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (06) : 1629 - 1636
  • [28] Nakahira S, 2008, ANTICANCER RES, V28, P179
  • [29] Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer
    Perri, Giampaolo
    Prakash, Laura
    Wang, Huamin
    Bhosale, Priya
    Varadhachary, Gauri R.
    Wolff, Robert
    Fogelman, David
    Overman, Michael
    Pant, Shubham
    Javle, Milind
    Koay, Eugene
    Herman, Joseph
    Kim, Michael
    Ikoma, Naruhiko
    Tzeng, Ching-Wei
    Lee, Jeffrey E.
    Katz, Matthew H. G.
    [J]. ANNALS OF SURGERY, 2021, 273 (04) : 806 - 813
  • [30] Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators
    Shirasaka, T
    Shimamato, Y
    Ohshimo, H
    Yamaguchi, M
    Kato, T
    Yonekura, K
    Fukushima, M
    [J]. ANTI-CANCER DRUGS, 1996, 7 (05) : 548 - 557